Implantable cardioverter-defibrillators (ICDs) have prevented cardiac arrests and deaths, but they carry a risk of giving patients shocks when they don’t need them. That inappropriate shock rate has been estimated as occurring in 10 to 20% of patients with the devices, causing unnecessary hospital admissions, and a negative impact on patients’ quality of life. They are also associated with increased morbidity and mortality for some patients.
But in a study in Heart Rhythm Angelo Auricchio, MD, PhD, and colleagues report on technological improvements in a Medtronic device that has reduced those shocks to 1.5% with a dual/triple chamber defibrillator and 2.5% for a single chamber ICD after one year.
Just 3 days before the state hosts the nation’s biggest sporting event, public health officials in Arizona are locked in an off-the-field battle with a different kind of opponent.
Phosphodiesterase type 5 inhibitor use after radical prostatectomy is associated with increased risk of biochemical recurrence, according to a study published in the February issue of The Journal of Urology.